Science Corporation valued at $3.5B after $400M funding round

Funding and Valuation

Science Corporation, a medical technology start-up founded in 2021 by former Neuralink president Max Hodak, has raised $400 million in a Series D funding round. This investment has led to a valuation of $3.5 billion, as reported by sources familiar with the deal.

Commercial Device and Trials

The company’s first product, PRIMA, is a wearable and implantable chip designed to help restore vision for individuals suffering from age-related macular degeneration. Currently, PRIMA is approved in Europe and available in Germany. Additionally, Hodak announced that the device is being trialed for patients with Stargardt’s disease, a condition that also causes vision loss.

Regulatory Path and U.S. Plans

With the new funding, Science Corporation aims to enter the U.S. market through the FDA’s Humanitarian Device Exemption (HDE). The company has argued that advanced macular degeneration affecting both eyes is rare enough to qualify for this pathway, which allows the use of experimental medical devices for uncommon conditions.

Long-term Research Direction

Beyond its immediate focus on restoring vision, Science Corporation has a long-term goal of developing a bio-hybrid sensor that integrates cultured neurons with silicon to interface directly with the human brain. The company is currently designing initial human trials for this technology in collaboration with Yale neurosurgery professor Murat Günel, who noted that it could potentially provide treatments for Parkinson’s disease and other neurological conditions. While the company prioritizes the commercialization of PRIMA and its regulatory efforts in the U.S., it continues to advance its research on neuron-silicon bio-hybrid devices and plans early human studies with academic partners.


Original source: TechCrunch AI

Leave a Comment